Trimurtulu Golakoti

Trimurtulu Golakoti

Auto-generated profile, based on publicly available information

Trimurtulu Golakoti

Laila Nutraceuticals R&D Center, Vijayawada, Andhra Pradesh, India

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
KAKrishnaraju Venkata Alluri
Krishnaraju Venkata Alluri
SKSreenath Kundimi
Sreenath Kundimi
KSKrishanu Sengupta
Krishanu Sengupta
TGTrimurtulu Golakoti
Trimurtulu Golakoti
EKEswar Kumar Kilari
Eswar Kumar Kilari
The boswellic acids, the active compounds in Boswellia serrata gum resin extract, are potent anti‐inflammatory agents and are specific nonredox inhibitors of 5‐Lipoxygenase (5‐LOX). Here, we present the anti‐osteoarthritis (OA) efficacy of LI13019F1 (also known as Serratrin®), a unique composition containing the acidic and nonacidic fractions of B. serrata gum resin. This composition strongly inhibited 5‐LOX activity with the half‐maximal inhibitory concentration (IC50) of 43.35 ± 4.90 μg/mL. Also, LI13019F1 strongly inhibited the leukotriene B4 (IC50, 7.80 ± 2.40 μg/mL) and prostaglandin E2 (IC50, 6.19 ± 0.52 μg/mL) productions in human blood‐derived cells. Besides, LI13019F1 reduced TNF‐α production with the IC50 of 12.38 ± 0.423 μg/mL. On average, 1, 2.5, and 5 μg/mL doses of LI13019F1 protected 34.62, 47.66, and 62.29% SW1353 human chondrosarcoma cells from IL‐1β induced SOX‐9 depletion, respectively. Further, a 28‐day preclinical proof‐of‐concept study evaluated the pain relief efficacy of LI13019F1 in monoiodoacetate‐ (MIA‐) induced Sprague-Dawley rats. At the end of the study, 150 and 300 mg/kg doses of LI13019F1 supplemented rats showed significant improvements (55.17 ± 5.81 g (p < 0.05), and 66.22 ± 6.30 g (p < 0.05), respectively, vs. MIA: 31.22 ± 7.15 g) in body‐weight‐bearing capacities. Concurrently, LI13019F1‐150 and LI13019F1‐300 rats substantially (p < 0.05) increased the threshold of pain sensitivity to pressure (26.98 ± 2.36 and 28.06 ± 2.72‐gram force, respectively; vs. 18.63 ± 5.82 in MIA) and increased (p < 0.05) the latent time to withdraw the paw after a thermal stimulus (23.61 ± 2.73 and 28.18 ± 1.90 sec, respectively; vs. 16.56 ± 1.22 sec. in MIA). Besides, the histological observations on Safranin‐O green stained articular cartilage revealed that LI13019F1 also prevented the MIA‐induced structural damage of the cartilage and reduced the loss of the extracellular matrix (ECM) components in the experimental rats. In conclusion, the present observations suggest that LI13019F1, a new composition of B. serrata gum resin extracts, reduces pain and protects articular cartilage from the damaging action of MIA in a rodent model.

MKManikyeswara Rao Konda
Manikyeswara Rao Konda
KAKrishnaraju Venkata Alluri
Krishnaraju Venkata Alluri
PJPrason Kumar Janardhanan
Prason Kumar Janardhanan
GTGolakoti Trimurtulu
Golakoti Trimurtulu
KSKrishanu Sengupta
Krishanu Sengupta
A proprietary composition GMCT contains extracts of two popular Asian herbs viz., Garcinia mangostana (GM) fruit rind and Cinnamomum tamala (CT) leaf. We systematically evaluated physical performance and muscle strength enhancing ability of GMCT in a preclinical mouse model followed by a 42-days double-blind placebo controlled human trial in resistance trained adult males. Four groups of Swiss albino mice (20–30 g body weight) (n = 6) were fed a standard laboratory diet and given Carboxymethylcellulose sodium (CMC), 150 mg/kg GMCT (GMCT-150), 300 mg/kg GMCT (GMCT-300) or 50 mg/kg Oxymetholone (OXY) via oral gavage for 21 days. On day 22, the animals’ physical performance and muscle strength were assessed in a forced swimming test (FST) and forelimb grip strength experiment, respectively. In the human trial, thirty-eight resistance-trained young adults (mean age 26.32 ± 4.39 years, body weight 67.79 ± 12.84 kg, BMI 22.92 ± 3.54 kg/m2) completed the trial. The participants received either GMCT (n = 19; 800 mg daily) or matched placebo (n = 19) for 42 days. As primary variables, 1-RM bench press, 1-RM leg press, and leg extension repetitions were measured at baseline and on days 14, 28 and 42 of the intervention. Anthropometric parameters and serum markers such as free testosterone, insulin-like growth factor 1 (IGF-1), insulin and lactate were also measured before and after the intervention. GMCT-300 mice showed significant improvement in swimming time (GMCT: 395.3 ± 81.70 s vs. CMC: 271.6 ± 56.86 s; p = 0.0166), distance (GMCT: 341.22 ± 65.88 m vs. CMC: 260.84 ± 49.15 m; p = 0.0461) and grip strength (GMCT: 43.92 ± 6.97 N vs. CMC: 35.0 ± 6.92 N; p = 0.0490), compared with the CMC group. At the end of the 42-day human trial, the per protocol analyses reveal that mean changes from baseline 1-RM bench press (GMCT: 23.47 ± 10.07 kg vs. PL: 3.42 ± 2.06 kg; p < 0.0001), leg press (GMCT: 29.32 ± 16.17 kg vs. PL: 5.21 ± 1.72 kg; p < 0.0001), number of leg extension repetitions (GMCT: 6.58 ± 2.57 vs. PL: 2.05 ± 1.22; p < 0.0001) in GMCT group were significantly improved, compared with placebo. Intergroup difference analyses show that the changes from baseline left arm (GMCT: 1.09 ± 0.36 cm vs. PL: 0.68 ± 0.42 cm; p = 0.0023), right arm (GMCT: 1.50 ± 0.44 cm vs. PL: 1.11 ± 0.43 cm; p = 0.0088) circumference and lean mass (GMCT: 2.29 ± 2.09 kg vs. PL: 0.52 ± 2.58 kg; p = 0.0404) in GMCT group were also significantly improved, compared with placebo. In comparison to placebo, GMCT supplementation did not improve free testosterone, IGF-1, insulin or lactate levels. Parameters of clinical biochemistry, hematology, urine and vital signs of the participants were within the normal range. GMCT supplementation is effective in increasing muscle strength, muscle size and, total lean mass, as well as endurance performance. Trial Registration. Clinical Trial Registry of India (CTRI/2015/01/005374), Registered on Jan 07, 2015; CTRI Website URL - http://ctri.nic.in

6 May 2022 in Journal of Toxicology
Verified
Journal Article
Open access
PDF file
RMRavi Kumar Madireddy
Ravi Kumar Madireddy
KAKrishnaraju Venkata Alluri
Krishnaraju Venkata Alluri
VSVenkateswarlu Somepalli
Venkateswarlu Somepalli
TGTrimurtulu Golakoti
Trimurtulu Golakoti
KSKrishanu Sengupta
Krishanu Sengupta
LN18178 (Tesnor®) is a standardized, proprietary composition of aqueous ethanol extracts of Punica granatum fruit rind and Theobroma cacao seeds. The present study demonstrates a broad-spectrum toxicological evaluation of LN18178 utilizing in vitro and in vivo preclinical models following the Organization for Economic Cooperation and Development (OECD) guidelines for testing chemicals. Wistar rats did not show any clinical signs of toxicity and morbidity in acute oral and dermal toxicity tests with the median lethal dose (LD50) values of at least 5000mg/kg and 2000mg/kg body weight, respectively. LN18178 was nonirritating to the skin and eyes of the treated rabbits. In a ninety-day subchronic repeated oral dose toxicity study, the LN18178-treated Wistar rats did not show dose-related signs of toxicity on their body weight, food consumption, organ weights, hematology, and clinical chemistry parameters. The estimated no-observed-adverse-effect level (NOAEL) of LN18178 in male and female rats was 2500mg/kg body weight. The observations from the bacterial reverse mutation test, in vitro chromosomal aberration assay, micronucleus assay in mouse bone marrow erythrocytes, and in vitro mouse lymphoma TK+/− gene mutation assay suggest that LN18178 is neither mutagenic nor clastogenic. In summary, the present study demonstrates that oral consumption of the herbal blend LN18178 does not show signs of toxicity; also it does not elicit genetic toxicity in the standard preclinical models.

1 April 2013 in Natural Product Communications
Verified
Journal Article
Open access
PDF file
SSShaik Khadar Shahabuddin
Shaik Khadar Shahabuddin
MRMunikishore Rachakunta
Munikishore Rachakunta
GTGolakoti Trimurtulu
Golakoti Trimurtulu
DGDuvvuru Gunasekar
Duvvuru Gunasekar
ADAlexandre Deville
Alexandre Deville
BBBernard Bodo
Bernard Bodo
Two new chalcones, 3-hydroxy-3′,4′-dimethoxychalcone (1) and 3,2′-dihydroxy-3′,4′-dimethoxychalcone (2),were isolated from the flowers of Clerodendrum inerme (L.) Gaertn together with two known flavones, 7-O-methylwogonin (3) and eucalyptin (4). The structures of the new compounds 1 and 2 have been established by extensive 2D-NMR and ESI-TOFMS studies.

1 September 2015 in Natural Product Communications
Verified
Journal Article
Open access
PDF file
LELakshmareddy Emani
Lakshmareddy Emani
SRSuryachandrarao Ravada
Suryachandrarao Ravada
BMBharani Meka
Bharani Meka
MGMachiraju Garaga
Machiraju Garaga
TGTrimurtulu Golakoti
Trimurtulu Golakoti
Chromolaena odorata (Syn: Eupatorium odoratum) is a perennial plant belonging to the Asteraceae family. Extracts of C. odorata have shown strong anti-oxidant and moderate anti-adipogenenesis activities. Detailed phytochemical investigation of C. odorata led to the isolation of 21 secondary metabolites, which include a new flavanone (3), and a chalcone, 3,2′-dihydroxy-4,4′,5′,6′-tetramethoxychalcone (2), reported for the first time from a natural source, besides three known compounds 1, 4 and 5, all of which are reported for the first time from C. odorata. Some of these compounds exhibited potent anti-oxidant and anti-adipogenesis activities and these may be partly responsible for the activity of the extract.

1 January 2024 in Journal of Toxicology
Verified
Journal Article
Open access
SDSundararaju Dodda
Sundararaju Dodda
SPSujatha Polavarapu
Sujatha Polavarapu
KAKrishnaraju Venkata Alluri
Krishnaraju Venkata Alluri
TGTrimurtulu Golakoti
Trimurtulu Golakoti
KSKrishanu Sengupta
Krishanu Sengupta
LN19183 is a standardized composition of Citrus aurantifolia (Christm) Swingle (CA) fruit rind and Theobroma cacao L. (TC) seed extracts that have recently been demonstrated to increase resting energy expenditure (REE) and reduce body fat in rats. CA and TC are important herbs in traditional medicine for various health benefits. The present study evaluates the comprehensive toxicity of LN19183 in acute, subchronic, and genetic toxicity studies following the guidelines of the Organization for Economic Co‐operation and Development (OECD) for testing chemicals. The acute oral and dermal and 90‐day subchronic oral toxicities were performed in rats, and acute dermal and eye irritations were performed in rabbits. In the subchronic toxicity study with a 28‐day recovery period, male and female Sprague Dawley rats were orally gavaged with daily LN19183 doses of 500, 1000, or 2000 mg/kg body weight (BW). Furthermore, the genetic toxicity studies included mutagenicity in bacteria, chromosome aberration, and micronucleus assays in human blood mononuclear cells in vitro and micronucleus assay in Swiss albino mice bone marrow in vivo. Acute and subchronic repeat dose oral toxicity studies showed no adverse events, clinical signs, or mortality. All animals exhibited normal food and water intake and natural BW gain. In the 90‐day study, LN19183 did not induce major changes in hematology, biochemical evaluations, and urine analysis; gross and histopathological findings did not show any treatment‐related lesions or abnormality. The no observed adverse effect level (NOAEL) of LN19183 supplementation was 2000 mg/kg BW/day. In the genetic toxicity studies, LN19183 treatment did not show significant increases in the revertant bacterial colonies, chromosomal aberrations, or number of micronucleated cells. The present observations affirm that oral consumption of LN19183 is safe, and this botanical composition is nonmutagenic and nonclastogenic.